Back to Authors

Benatar, Michael

0000-0003-4241-5135

Mayo Clinic

St. Jude Children's Research Hospital

Citations 4

Toward therapeutic trials in primary lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | July 6, 2025 | Volume: 26 | Issue: 7-8 | Pages: 623-630

10.1080/21678421.2025.2527123 | PMID 40618376

Clinical testing panels for ALS: global distribution, consistency, and challenges

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | March 10, 2023 | Volume: 24 | Issue: 5-6 | Pages: 420-435

10.1080/21678421.2023.2173015 | PMID 36896705

Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis

Neurology Genetics | January 12, 2022 | Volume: 8 | Issue: 1 | Pages: No page available

10.1212/nxg.0000000000000654 | PMID 35047667

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis

Science Translational Medicine | March 29, 2017 | Volume: 9 | Issue: 383 | Pages: No page available

10.1126/scitranslmed.aai7866 | PMID 28356511

Poly(GP) proteins are a promising pharmacodynamic marker for developing and testing therapeutics for treating C9ORF72 -associated amyotrophic lateral sclerosis.